BioCentury
ARTICLE | Strategy

Broadening Novartis’ NET

Where Advanced Accelerator’s Lutathera fits into Novartis’ NET franchise

November 3, 2017 11:56 PM UTC

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease.

On Oct. 30, Novartis offered to acquire Advanced Accelerator for $82 per ADS in a deal that values the company at $3.9 billion. The price is a 39% premium on its close of $59.76 on Sept. 27, before media reports said the two companies had entered M&A discussions. ...

BCIQ Target Profiles

Somatostatin